?Phentolamine Mesilate | ?? Non-Selective α-Blocker | ?? Rapid Vasodilator for Hypertension & Raynaud’s | ? USP/EP Grade?

??? Product Overview?

Phentolamine Mesilate is a ?non-selective α-adrenergic receptor antagonist? that rapidly reverses vasoconstriction and lowers blood pressure?13. It is clinically used to manage ?hypertensive crises? and ?Raynaud’s syndrome? by blocking α1/α2 receptors, improving blood flow and reducing ischemia?14. With ?>99% HPLC-verified purity?, it meets stringent pharmacopeial standards for therapeutic applications?24.

?? Key Benefits?

• ??? Rapid Onset?

  : Achieves blood pressure reduction within 

  ?30 minutes? of administration?.
• ??? Dual α1/α2 Blockade?

  : Ensures balanced vasodilation and reduced cardiac workload?34.

• ??? High Purity?

  : ?HPLC >99%? and ?GC-MS validated?, minimizing impurities?.

??? Applications?

1. ?Hypertensive Emergencies?

   : Controls acute blood pressure spikes?13.

2. ?Raynaud’s Disease?

   : Alleviates vasospasm-induced pain and ischemia?12.

3. ?Diagnostic Testing?

   : Identifies pheochromocytoma via catecholamine reversal?15.

?? Quality Certifications?

• Complies with ?USP/EP? monographs for APIs?.

• Rigorous ?residual solvent analysis? (GC-MS) and ?batch-specific COA? provided?.

??? Market Trends?

The global ?hypertension drug market? is projected to grow at ?5.8% CAGR (2025–2030)??6, driven by rising cardiovascular disease prevalence (affecting ?1.3 billion adults? worldwide)?5. Phentolamine remains a critical agent in emergency and niche vascular therapies?16.

?Keywords?: Non-selective alpha blocker, vasodilator drug, hypertensive crisis treatment, Raynaud’s syndrome medication, USP-grade API

Citations: ?12 | Updated: Feb 2025